Osteopenia, Osteoporosis Clinical Trial
— ACTLIFEOfficial title:
Effects of an Optimized 13-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis (Actlife)
Verified date | June 2020 |
Source | University of Erlangen-Nürnberg Medical School |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Menopause usually have a serious impact on a woman's life, associated with negative
consequences for health and quality of life. Early preventive assessments are very difficult
to implement due to the complex hormone-deficiency-induced effects on a large variety of
organs and systems with estrogen receptors. In fact, only a few types of interventions have
the potential to comprehensively improve the various risk factors and complaints of the
menopausal transition. In detail, however, not every form of exercise training or every
training protocol is effective for exerting positive effects on selected risk factors. In
particular, the training concept for addressing musculoskeletal or cardio-metabolic risk
factors differ fundamentally.
In several studies, we confirmed the effect of different complex training programs on risk
factors of different postmenopausal female cohorts with special consideration of osteoporotic
aspects. The training programs applied in this context were characterized by the consistent
implementation of recognized training principles and an in general exercise
intensity-oriented approach. Recent studies confirmed the effectiveness of this proceeding
for women with relevant postmenopausal risk factors including low bone strength. However, the
crucial issue of the most effective, feasible and easily customizable training protocol for
addressing postmenopausal risk factors remains to be answered, taking into account that the
majority of exercise programs were realized in an ambulatory group setting.
The aim of the study will be to evaluate the effects of an optimized physical training on
risk factors and complaints of (early) postmenopausal women with special consideration of the
osseous fracture risk.
Note (05.06.2020): Of importance, the intervention has to be cancelled due to COVID-19
lockdown in March 2020 after 13 months of intervention.
Status | Completed |
Enrollment | 27 |
Est. completion date | June 5, 2020 |
Est. primary completion date | March 13, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 48 Years to 58 Years |
Eligibility |
Inclusion Criteria: - (early)postmenopausal women, ( normal menopause, 1-5 years post) - Osteopenia and osteoporosis at the lumbar spine or femoral neck Bone Mineral Density (BMD) <-1.0 standard deviation (SD) T-Score, WHO) Exclusion Criteria: - BMD <-4.0 SD T-Score (BMD threshold for pharmaceutical therapy according to Dachverband Osteologie (DVO) guideline (mandatory for Germany, Austria, Suisse) for woman 50-60 years). - Prevalent clinical, low-trauma fractures - Diseases and drugs with relevant effects on bone and muscle metabolism (e.g. glucocorticoids >7.5 mg/d or bisphosphonate therapy); individual case assessment - Diseases and drugs with relevant effects on cardiometabolic risk factors (e.g. severe hypertension with corresponding medical therapy); individual case assessment - Severe cardiovascular events (e.g. stroke, coronary infarction) in the past. - Other conditions, diseases that exclude exercise training in a group (=10 persons). |
Country | Name | City | State |
---|---|---|---|
Germany | Institute of Medical Physics, Friedrich Alexander University Erlangen-Nürnberg | Erlangen | Bavaria |
Lead Sponsor | Collaborator |
---|---|
University of Erlangen-Nürnberg Medical School |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | BMD Lumbar Spine | Bone Mineral Density (BMD) at the lumbar spine region of interest as determined by Dual Energy x-Ray Absorptiometry (DXA) | from baseline to 13 month follow-up | |
Secondary | BMD total Hip | Bone Mineral Density at the total hip region of interest as determined by DXA | from baseline to 13 month follow-up | |
Secondary | Para-vertebral muscle density | Muscle density at the para-vertebral region as determined by Magnetic Resonance Imaging (MRI) | from baseline to 13 month follow-up | |
Secondary | Mid-thigh muscle density | Muscle density at the mid-thigh region as determined by MRI | from baseline to 13 month follow-up | |
Secondary | Metabolic Syndrome | Metabolic Syndrome Z-Score according to the Internationale Diabetes Federation (IDF) | from baseline to 13 month follow-up | |
Secondary | Visceral body fat | Visceral body fat as determined by Magnetic Resonance Imaging (MRI) | from baseline to 13 month follow-up | |
Secondary | Total body fat | Total body fat as determined by whole body DXA | from baseline to 13 month follow-up | |
Secondary | Total Lean Body Mass | Total Lean Body Mass as determined by whole body DXA | from baseline to 13 month follow-up | |
Secondary | Menopausal complaints | Menopausal complaints as determined by the Menopause Rating Scale (German version. Questionnaire with 11 items; scale from 0 (no complaints/problems) to 4 (very severe complaints/problem) | from baseline to 13 month follow-up | |
Secondary | Maximum leg strength | Maximum isokinetic leg extensor strength as determined by an isokinetic leg press | from baseline to 13 month follow-up | |
Secondary | Total fat rate | Total fat rate as determined by Bio Impedance technique (BIA) | from baseline to 13 month follow-up | |
Secondary | Fat free mass | Fat free mass as determined by BIA | from baseline to 13 month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06018467 -
Senolytics to Improve Osteoporosis Therapy
|
Phase 2 | |
Completed |
NCT04122638 -
Prevalence of Sarcopenia and Sarcopenic Obesity in Older Adults
|
||
Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
Completed |
NCT03819478 -
Utilizing Protein During Weight Loss to Impact Physical Function and Bone
|
N/A | |
Recruiting |
NCT01857154 -
A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate
|
N/A | |
Not yet recruiting |
NCT04719572 -
Intervention Study of Drugs in Patients Osteopenia and Osteoporosis
|
N/A | |
Active, not recruiting |
NCT04708886 -
Romosozumab in Women With Chronic SCI
|
Phase 2 |